Pharmaceuticals

Biotech leader Arrowhead Pharmaceuticals prices upsized offerings, signaling strong investor confidence and fueling its next wave of RNAi therapies.

The pharmaceutical giant is expanding its partnership with Veeva, adopting a next-gen CRM with agentic AI to transform its global commercial execution.

Dexcel Pharma USA acquires Zubsolv®, a key opioid addiction therapy, signaling a major strategic shift into the branded drug market in the U.S.

Acertis Pharmaceuticals secures rights to Licart, a unique once-daily NSAID patch, aiming to disrupt the competitive U.S. topical pain relief market.

Employer health plans are using 'alternative funding' to cut costs, but critics warn these schemes force patients to use risky, non-FDA approved drugs.

The national civil rights firm promotes four lawyers, bolstering its ranks with diverse experts in victims' rights, LGBTQ+ advocacy, and complex litigation.

The deal merges digital orchestration with field AI, promising pharma a unified, rapid-deployment engagement solution to challenge industry giants.

Backed by Frazier Healthcare Partners, the new CareTria aims to slash patient wait times for medication with a powerful, end-to-end technology platform.

Pharma giant Lilly and AI biotech BigHat are teaming up to solve a critical flaw in AI drug discovery, aiming to unlock a new generation of therapies.

The deal creates an end-to-end commercialization powerhouse, tackling pharma's toughest payer, reimbursement, and patient affordability challenges.

With $16.4M in new funding, STRM.BIO is advancing a novel gene therapy platform that uses natural vesicles to target bone marrow, offering new hope for rare diseases.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

A new patient app from BrightInsight and Sanofi reduced therapy discontinuation by 4%, proving digital tools can solve medicine's adherence problem.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With a massive $200M Series C, Soley Therapeutics is using its AI cell-sensing platform to fast-track novel cancer drugs from code to clinic.

Pharma giant Bayer partners with AI innovator Cradle, betting on generative AI to accelerate its biologics pipeline and reshape modern medicine.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.

A new alliance pairs Relation's 'Lab-in-the-Loop' AI with Deerfield's investment might, aiming to fast-track novel drugs for intractable diseases.